Detection rate of GRPR-targeted PET in PSMA-negative prostate cancer in biochemical recurrence as a function of serum PSA and Gleason score

Detection rate of GRPR-targeted PET in PSMA-negative prostate cancer in biochemical recurrence as a function of serum PSA and Gleason score - GRPR PSMA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033105

Enrollment

Registered

2023-12-19

Start date

2023-09-12

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OPS-Code 3-75: Positron emission tomography with computed tomography [PET/CT] PSMA Patients

Interventions

Group 1: one-time GRPR-directed PET in PSMA-negative prostate cancer

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: histologically confirmed prostate carcinoma after primary prostatectomy or radiotherapy, biochemical recurrence (PSA > 0.2 ng/ml after prostatectomy or increase in PSA more than 2.0 ng/ml above the nadir after definitive radiotherapy). All patients must have received a GRPR-directed PET as part of the clinical routine after a negative PSMA-PET/CT

Exclusion criteria

Exclusion criteria: Not available

Design outcomes

Primary

Measure	Time frame
Detection rate of recurrence in patients with biochemical recurrence of PSMA-negative prostate cancer	—

Secondary

Measure	Time frame
Correlation of the detection rate to the initial Gleason score Correlation of the detection rate to the PSA value at the time of imaging Change in therapeutic management due to imaging	—

Countries

Germany

Contacts

Public ContactConstantin Lapa

Universitätsklinikum Augsburg, Klinik für Nuklearmedizin

Nuk.Studien@uk-augsburg.de+498214002050

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026